RECURRENT OR REFRACTORY GLYPICAN 3 (GPC3)

Clinical trials for RECURRENT OR REFRACTORY GLYPICAN 3 (GPC3) explained in plain language.

Never miss a new study

Get alerted when new RECURRENT OR REFRACTORY GLYPICAN 3 (GPC3) trials appear

Sign up with your email to follow new studies for RECURRENT OR REFRACTORY GLYPICAN 3 (GPC3), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for kids with Tough-to-Treat cancers

Disease control Recruiting now

This study is testing whether codrituzumab is safe for children and young adults with solid tumors that have returned or stopped responding to standard treatments. Researchers will give the drug to up to 50 patients aged 1-21 years to check for side effects and see how the body p…

Matched conditions: RECURRENT OR REFRACTORY GLYPICAN 3 (GPC3)

Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control

Last updated Mar 23, 2026 15:19 UTC

RECURRENT OR REFRACTORY GLYPICAN 3 (GPC3)

Get alerted when new RECURRENT OR REFRACTORY GLYPICAN 3 (GPC3) trials appear

New hope for kids with Tough-to-Treat cancers